Semaglutide
Cross-source consensus on Semaglutide from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Benefits
Risks & contraindications
Comparisons
Highlighted claims
- Wegovy is approved for cardiovascular risk reduction in adults with established ASCVD and BMI ≥27 who do not have diabetes. — GLP-1 Medications: A Comprehensive Clinical Guide
- Semaglutide (Wegovy) achieves approximately 10–15% weight loss for weight management. — GLP-1 Medications: A Comprehensive Clinical Guide
- Oral semaglutide (Rybelsus) is the only oral GLP-1 receptor agonist available. — GLP-1 Medications: A Comprehensive Clinical Guide
- Patients who switch from semaglutide to placebo after an initial run-in period regain substantially lost weight. — GLP-1 Medications: A Comprehensive Clinical Guide
- Up to 40% of weight lost on semaglutide may derive from lean muscle mass rather than fat, based on STEP 1 and SUSTAIN 8 trial data. — GLP-1 Medications: A Comprehensive Clinical Guide